PureTech Health (LSE:PRTC) Institutional Ownership: 33.21% (As of Jul. 11, 2026)


LSE:PRTC PureTech Health PLC LSE:PRTC
63 GF Score
Price £1.20
GF Value £5.31
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is PureTech Health Institutional Ownership?

PureTech Health LSE:PRTC +0.50% 63 Institutional Ownership is 33.21% as of Jul. 11, 2026. GuruFocus rates LSE:PRTC with a GF Score™ of 63/100 and a GF Value™ of £5.31 (Possible Value Trap). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PureTech Health's institutional ownership is 33.21%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PureTech Health's Insider Ownership is 13.35%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PureTech Health's Float Percentage Of Total Shares Outstanding is 83.13%.

PureTech Health Institutional Ownership Historical Data

* Premium members only.

The historical data trend for PureTech Health's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PureTech Health Institutional Ownership Chart

PureTech Health Historical Data

The historical data trend for PureTech Health can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 38.57 38.17 37.51 36.02 35.61 34.75 33.27 33.22 33.19 33.21
LSE:PRTC
63GF Score
PureTech Health PLC LSE:PRTC
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PureTech Health Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 33.21% mean?
PureTech Health (LSE:PRTC) has a Institutional Ownership of 33.21% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on PureTech Health and its competitors.
Is PureTech Health's Institutional Ownership too high?
PureTech Health's current Institutional Ownership is 33.21%. Overall, PureTech Health has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Institutional Ownership compare to VRTX and REGN?
PureTech Health's Institutional Ownership of 33.21% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on PureTech Health and its competitors. PureTech Health's current Institutional Ownership is 33.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (LSE:PRTC) is currently considered Possible Value Trap. The stock's GF Value™ is £5.31, compared to a current price of £1.20 — trading 77.4% below its estimated fair value. The current Institutional Ownership is 33.21%. PureTech Health's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For PureTech Health (LSE:PRTC), the current Institutional Ownership is 33.21% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PureTech Health (LSE:PRTC) Overvalued in 2026?

Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued. The current stock price of £1.20 is trading 77.4% below its estimated GF Value™ of £5.31. GuruFocus considers PureTech Health to be Possible Value Trap.

Key valuation signals for LSE:PRTC:

  • Institutional Ownership: 33.21%
  • GF Value™: £5.31 vs. price of £1.20 (77.4% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the LSE:PRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PureTech Health Business Description

Address 6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
63GF Score

Get the complete analysis for LSE:PRTC

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£1.20
Price
£5.31
GF Value